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Background: Erlotinib (Tarceva®) is the ﬁrst EGFR tyrosine kinase 
inhibitor which demonstrated the survival beneﬁt to non-small cell lung 
cancer (NSCLC) patients. An expanded access program was designed 
to provide Erlotinib to NSCLC patients and evaluate the efﬁcacy and 
safety of Erlotinib in Taiwanese population.
Methods: Patients with proven stage IIIB/IV NSCLC and received 
at least one course of standard systemic chemotherapy or radiation 
therapy were enrolled in this study. No more than 2 prior chemotherapy 
regimens are permissible. All patients were given oral erlotinib, 150 
mg/d till disease progression, according to the criteria of RECIST. Pa-
tients were monitored monthly and tumor assessments were evaluated 
every 2 months by x-ray, CT, or MRI.
Results: From Apr. 2005 to Feb. 2006, 297 patients were registered 
from 15 medical centers in Taiwan. The interim study evaluated the 
297 patients (53% male; median age 62 [27-84]). 80% patients were 
with ECOG PS 0-1. Most patients had adenocarcinoma (67%) and 
squamous cell carcinoma (20%). 62 % of patients receiving erlotinib as 
2nd-line treatment. 44% of patients were current-smoker. The proﬁle of 
297 patients was similar to the above baseline characteristics. The best 
response rate was 25% PR and 42% SD according to RECIST (disease 
control rate= 73%). The time to progression (TTP) analysis for all pa-
tients was based on 297 patients with 89 censored observations (30%). 
Due to the high number of censored observations it is too early to 
assess the median TTP for the overall population. Overall survival was 
also assessed for patients on 2nd and 3rd line treatment. Due to the high 
number of censored observations it is too early to assess the median 
survival by treatment line. As expected, rash was a common adverse 
event (any grade [gr]: 83%; gr 3-4: 15%). Skin toxicity (gr 3-4 vs. gr 
0-2) was signiﬁcantly correlated with best response (Chi-sq p value 
0.0095). Erlotinib-related AEs were seen in 29% patients. Erlotinib-
related AEs leading to treatment discontinuation were seen in 8 patients 
due to GI disorder, GOT/GPT elevation, skin toxicity, dyspnea or 
pneumonitis. There were 24% of patients had dose reductions, mainly 
due to rash (66%) and diarrhea (2%). Erlotinib-related SAEs were seen 
in 4% of patients, mainly GI disorders (2%). 
Conclusions: This is the largest multicenter prospective clinical study 
of NSCLC in Taiwan. This interim result demonstrated the superb 
response rates, time-to-progression and overall survival of erlotinib in a 
large population of East Asian advanced chemotherapy-treated NSCLC 
patients.
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Erlotinib in advanced squamous cell carcinoma of the lung
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Background: Erlotinib, an oral HER-1/EGFR TKI is approved for 
patients with locally advanced or metastatic non-small cell lung cancer 
(NSCLC) after failure of at least one prior chemotherapy regimen. 
Retrospective analysis have shown that adenocarcinoma histology to-
gether with female gender, Asian origin, and never having smoked are 
associated with responsiveness of NSCLC to erlotinib. The purpose of 
the analyisis we present here was to describe the outcome in a group of 
patients with squamous carcinoma of the lung treated with Erlotinib.
Methods: The TargeT trial was an open-label multicenter clinical trial 
carried out in 103 Spanish institutions. Chemonaïve or previously treat-
ed patients (p) with conﬁrmed NSCLC (stage IIIB-IV), PS 0-2, age ≥ 
18 years, adequate organ functions and having given written informed 
consent were treated with 150 mg/day po until disease progression or 
unacceptable toxicity. Primary end-point of the trial was survival.
Results: Between April 2004 and March 2006, 384 patients with 
histological diagnosis of squamous cell lung cancer were enrolled 
in the TargeT study. Demographics are as follows: median age 67 y 
(range 36-86); 92% of pts were men (352) and 96% were active or 
former smokers (367); 72% had stage IV NSCLC and 81% (314 pts) 
have received previous treatment for metastatic disease; PS 0/1/≥2 
72(19%)/227 (59%)/85 (22%). In the evaluable population for response 
(233 pts) 21 PR (9%) and 1 CR (0.4%) were observed for an overall 
RR of 9.4 %. Clinical beneﬁt deﬁned as CR+PR+SD was 56%. In 
the ITT populations median TTP was 3.8 months [95% CI 3.2-4.8]. 
Median OS was 6.2 m [95% CI 5.5-6.7]. In the multivariate analysis 
only PS remained as a predictive factor for a longer overall survival (p 
< 0.0001).
Erlotinib was well tolerated and non unexpected toxicities were ob-
served. 
Conclusions: This retrospective analysis conﬁrms that erlotinib is ac-
tive and well tolerated in patients with advanced or metastatic squa-
mous cell carcinoma of the lung. Responses were seen in both genders 
and in patients with or without smoking history. In agreement with our 
data, at this moment histology should not be used as the only selection 
criteria for treatment of patients with NSCLC after failure to chemo-
therapy. 
